Shire paying $5.2bn for rare disease specialist NPS
Shire will put its $1.6bn cash breakup fee from AbbVie – and then some – to use via the Dublin-based company's $5.2bn acquisition of NPS Pharmaceuticals.
Shire will put its $1.6bn cash breakup fee from AbbVie – and then some – to use via the Dublin-based company's $5.2bn acquisition of NPS Pharmaceuticals.